Effect of matrix metalloproteinase inhibition by doxycycline on myocardial healing and remodeling after myocardial infarction

Cardiovascular Drugs and Therapy

Volumn 19, Issue 6, 2005, Pages 383-390

  Tessone, Ariel ^a   Feinberg, Micah S ^a   Barbash, Israel M ^a   Reich, Reuven ^b   Holbova, Radka ^a   Richmann, Michal ^b   Mardor, Yael ^c   Leor, Jonathan ^a,c  

^a TEL AVIV UNIVERSITY   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

Author keywords

Angiogenesis; Heart failure; Myocytes; Remodeling

Indexed keywords

DOXYCYCLINE; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE INHIBITOR; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DENSITY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; ENZYME INHIBITION; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HISTOLOGY; ISOLATED HEART; MALE; MORPHOMETRICS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; SCAR FORMATION; WOUND HEALING; ZYMOGRAPHY;

ANIMALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXYCYCLINE; ECHOCARDIOGRAPHY; ENZYME ACTIVATION; ENZYME INHIBITORS; HEART; IMMUNOHISTOCHEMISTRY; INJECTIONS, SUBCUTANEOUS; MAGNETIC RESONANCE IMAGING; MALE; MATRIX METALLOPROTEINASES; MYOCARDIAL INFARCTION; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; VENTRICULAR REMODELING; WOUND HEALING;

EID: 32444441006     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-005-5201-6     Document Type: Article

References (40)

1. Jugdutt BI. Ventricular remodeling after infarction and the extracellular collagen matrix: When is enough enough? Circulation 2003;108:1395-1403.
2. Mann DL. Mechanisms and models in heart failure: A combinatorial approach. Circulation 1999;100:999-1008.
3. Button MG, Sharpe N. Left ventricular remodeling after myocardial infarction: Pathophysiology and therapy. Circulation 2000;101:2981-2988.
4. Jessup M, Brozena S. Heart Failure. N Engl J Med 2003;348:2007-2018.
5. Villarreal FJ, Griffin M, Omens J, Dillmann W, Nguyen J, Covell J. Early short-term treatment with doxycycline modulates postinfarction left ventricular remodeling. Circulation 2003;108:1487-1492.
6. Creemers EE, Cleutjens JP, Smits JF, Daemen MJ. Matrix metalloproteinase inhibition after myocardial infarction: A new approach to prevent heart failure? Circ Res 2001;89:201-210.
7. Spinale FG, Gunasinghe H, Sprunger PD, Baskin JM, Bradham WC. Extracellular degradative pathways in myocardial remodeling and progression to heart failure. J Card Fail 2002;8:S332-S338.
8. Spinale FG, Coker ML, Bond BR, Zellner JL. Myocardial matrix degradation and metalloproteinase activation in the failing heart: A potential therapeutic target. Cardiovasc Res 2000;46:225-238.
9. Sun Y, Zhang JQ, Zhang J, Lamparter S. Cardiac remodeling by fibrous tissue after infarction in rats. J Lab Clin Med 2000;135:316-323.
10. Spinale FG. Matrix metalloproteinases: Regulation and dysregulation in the failing heart. Circ Res 2002;90:520-530.
11. Hayashidani S, Tsutsui H, Ikeuchi M, et al. Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. Am J Physiol Heart Circ Physiol 2003;285:H1229-H1235.
12. Ramani R, McTiernan CF. The matrix strikes back: Evidence for autoregulatory mechanisms in metalloproteinase regulation. J Mol Cell Cardiol 2003;35:603-606.
13. Petrinec D, Liao S, Holmes DR, Reilly JM, Parks WC, Thompson RW. Doxycycline inhibition of aneurysmal degeneration in an elastase-induced rat model of abdominal aortic aneurysm: Preservation of aortic elastin associated with suppressed production of 92 kD gelatinase. J Vasc Surg 1996;23:336-246.
14. Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JR, Sawicki G, Schulz R. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 2002;106:1543-1549.
15. Camp TM, Tyagi SC, Aru GM, Hayden MR, Mehta JL. Doxycycline ameliorates ischemic and border-zone remodeling and endothelial dysfunction after myocardial infarction in rats. J Heart Lung Transplant 2004;23:729-736.
16. Brown RD, Ambler SK, Mitchell MD, Long CS. The cardiac fibroblast: Therapeutic target in myocardial remodeling and failure. Annu Rev Pharmacol Toxicol 2005;45:657-687.
17. Etzion S, Battler A, Barbash IM, et al. Influence of embryonic cardiomyocyte transplantation on the progression of heart failure in a rat model of extensive myocardial infarction. J Mol Cell Cardiol 2001;33:1321-1330.
18. Lu L, Zhang JQ, Ramires FJ, Sun Y. Molecular and cellular events at the site of myocardial infarction: From the perspective of rebuilding myocardial tissue. Biochem Biophys Res Commun 2004;320:907-913.
19. Reich R, Blumenthal M, Liscovitch M. Role of phospholipase D in laminin-induced production of gelatinase A (MMP-2) in metastatic cells. Clin Exp Metastasis 1995;13:134-140.
20. Barbash IM, Leor J, Feinberg MS, et al. Interventional magnetic resonance imaging for guiding gene and cell transfer in the heart. Heart 2004;90:87-91.
21. Rohde LE, Ducharme A, Arroyo LH, et al. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 1999;99:3063-3070.
22. Ducharme A, Frantz S, Aikawa M, et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 2000;106:55-62.
23. Curci JA, Petrinec D, Liao S, Golub LM, Thompson RW. Pharmacologic suppression of experimental abdominal aortic aneurysms: Acomparison of doxycycline and four chemically modified tetracyclines. J Vasc Surg 1998;28:1082-1093.
24. Lamparter S, Slight SH, Weber KT. Doxycycline and tissue repair in rats. J Lab Clin Med 2002;139:295-302.
25. Lindsey ML, Gannon J, Aikawa M, et al. Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction. Circulation 2002;105:753-758.
26. Heissig B, Hattori K, Friedrich M, Rafii S, Werb Z. Angiogenesis: Vascular remodeling of the extracellular matrix involves metalloproteinases. Curr Opin Hematol 2003;10:136-141.
27. Puyraimond A, Weitzman JB, Babiole E, Menashi S. Examining the relationship between the gelatinolytic balance and the invasive capacity of endothelial cells. J Cell Sci 1999;112(Pt 9):1283-1290.
28. Haas TL, Milkiewicz M, Davis SJ, et al. Matrix metalloproteinase activity is required for activity-induced angiogenesis in rat skeletal muscle. Am J Physiol Heart Circ Physiol 2000;279:H1540-H1547.
29. Heissig B, Hattori K, Dias S, et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 2002;109:625-637.
30. Kollet O, Shivtiel S, Chen YQ, et al. HGF, SDF-1, and MMP-9 are involved in stress-induced human CD34+ stem cell recruitment to the liver. J Clin Invest 2003;112:160-169.
31. Johnson C, Sung HJ, Lessner SM, Fini ME, Galis ZS. Matrix metalloproteinase-9 is required for adequate angiogenic revascularization of ischemic tissues: Potential role in capillary branching. Circ Res 2004;94:262-268.
32. Creemers E, Cleutjens J, Smits J, et al. Disruption of the plasminogen gene in mice abolishes wound healing after myocardial infarction. Am J Pathol 2000;156:1865-1873.
33. Heymans S, Luttun A, Nuyens D, et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med 1999;5:1135-1142.
34. Minatoguchi S, Takemura G, Chen XH, et al. Acceleration of the healing process and myocardial regeneration may be important as a mechanism of improvement of cardiac function and remodeling by postinfarction granulocyte colony-stimulating factor treatment. Circulation 2004;109:2572-2580.
35. Yarbrough WM, Mukherjee R, Escobar GP, et al. Selective targeting and timing of matrix metalloproteinase inhibition in post-myocardial infarction remodeling. Circulation 2003;108:1753-1759.
36. Cleland JG, Coletta AP, Freemantle N, Velavan P, Tin L, Clark AL. Clinical trials update from the American College of Cardiology meeting: CARE-HF and the Remission of Heart Failure, Women's Health Study, TNT, COMPASS-HF, VERITAS, CANPAP, PEECH and PREMIER. Eur J Heart Fail 2005;7:931-936.
37. Lindsey M, Wedin K, Brown MD, et al. Matrix-dependent mechanism of neutrophil-mediated release and activation of matrix metalloproteinase 9 in myocardial ischemia/reperfusion. Circulation 2001;103:2181-2187.
38. Peterson JT, Hallak H, Johnson L, et al. Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation 2001;103:2303-2309.
39. Beekman B, Verzijl N, de Roos JA, Koopman JL, TeKoppele JM. Doxyclycline inhibits collagen synthesis by bovine chondrocytes cultured in alginate. Biochem Biophys Res Commun 1997;237:107-110.
40. Chapman RE, Scott AA, Deschamps AM, et al. Matrix metalloproteinase abundance in human myocardial fibroblasts: Effects of sustained pharmacologic matrix metalloproteinase inhibition. J Mol Cell Cardiol 2003;35:539-548.